All In Biotech

Drug Trial Radar · NCT01821391

Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses

Multi-centre, Randomized, Investigator-blind, Intra-individual Active and Vehicle-controlled Study, Comparing Metvix Natural Daylight Photodynamic Therapy Versus Metvix Conventional Photodynamic Therapy in Subjects With Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Jul 2013

Primary completion

Jan 2014

Study completion Mar 2014

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Apr 1, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was to be conducted as a multi-centre, randomized, investigator-blinded, active and vehicle-controlled, intra-individual (split-face/scalp) non-inferiority (regarding efficacy) and superiority (regarding pain) study. The primary purpose of this study is to demonstrate the non-inferiority of NDL-PDT compared to c-PDT in terms of lesion complete response rate.

Conditions

  • Actinic Keratoses

Interventions

  • NDL-PDTDrug

    Metvix natural daylight photodynamic therapy

  • c-PDTDrug

    Metvix conventional photodynamic therapy

  • placebo c-PDTDrug

    Metvix placebo conventional photodynamic therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage (%) Change From Baseline in Total Lesion Complete Response at Week 12 in Group 1Time frame: Baseline, Week 12

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • Investigative site

    Montpellier, France

  • Investigational site

    Nantes, France

  • Investigational site

    Nice, France

  • Investigational site

    Paris, France

  • Investigative site

    Rennes, France

  • Investigational site

    Aachen, Germany

  • Investigational site

    Berlin, Germany

  • Investigational site

    Münster, Germany

  • Investigational site

    Recklinghausen, Germany

  • Investigational site

    Assen, Netherlands

  • Investigational site

    Maastricht, Netherlands

  • Investigational site

    Nijmegen, Netherlands

  • Investigational site

    Huesca, Spain

  • Investigational site

    Madrid, Spain

  • Investigative site

    Pamplona, Spain

  • Investigational site

    Valencia, Spain

  • Investigational site

    Karlskoga, Sweden

  • Investigational site

    Norrköping, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.